Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126

Clinical Cancer Research

Volumn 10, Issue 11, 2004, Pages 3650-3657

  Evelhoch, Jeffrey L ^a   LoRusso, Patricia M ^a   He, Zhanquan ^a   DelProposto, Zachary ^a   Polin, Lisa ^a   Corbett, Thomas H ^a   Langmuir, Peter ^b   Wheeler, Catherine ^b   Stone, Andrew ^c   Leadbetter, Joanna ^c   Ryan, Anderson J ^c   Blakey, David C ^c   Waterton, John C ^c  

^a WAYNE STATE UNIVERSITY   (United States)

^b ASTRAZENECA   (United Kingdom)

^c NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE DERIVATIVE; GADOLINIUM PENTETATE; N ACETYLCOLCHINOL PHOSPHATE; TUBULIN;

ADULT; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD FLOW; BLOOD VESSEL INJURY; BLOOD VESSEL PERMEABILITY; CELL PROLIFERATION; CLINICAL ARTICLE; COLON ADENOCARCINOMA; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; EXTRACELLULAR SPACE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MOUSE; MUSCLE BLOOD FLOW; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TUMOR NECROSIS;

ANGIOGENESIS INHIBITORS; ANIMALS; AREA UNDER CURVE; CELL LINE, TUMOR; CELL PROLIFERATION; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GADOLINIUM DTPA; HUMANS; KINETICS; MAGNETIC RESONANCE IMAGING; MALE; MICE; NECROSIS; ORGANOPHOSPHORUS COMPOUNDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 2542523230     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0417     Document Type: Article

References (32)

1. Thorpe PE, Chaplin DJ, Blakey DC. The first international conference on vascular targeting: meeting overview. Cancer Res 2003;63:1144-7.
2. Micheletti G, Poli M, Borsotti P, et al. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 2003;63:1534-7.
3. Blakey DC, Douglas S, Revill M, Ashton SE. The novel vascular targeting agent ZD6126 causes rapid morphology changes leading to endothelial cell detachment at non-cytotoxic concentrations [abstract]. Clin Exp Metastasis 2000;17:776.
4. Blakey DC, Westwood FR, Walker M, et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002;8:1974-83.
5. Goto H, Yano S, Zhang H, et al. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice. Cancer Res 2002;62:3711-5.
6. Siemann DW, Rojiani AM. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002;54:1512-7.
7. Davis PD, Dougherty GJ, Blakey DC, et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002;62:7247-53.
8. Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002;53:164-71.
9. Radema SA, Beerepoot LV, Witteveen PO, Gebbink MF, Wheeler C, Voest EE. Clinical evaluation of the novel vascular-targeting agent, ZD6126: assessment of toxicity and surrogate markers of vascular damage. Proc Am Soc Clin Oncol 2002;21:110a.
10. Gadgeel SM, LoRusso PM, Wozniak AJ, Wheeler C. A dose-escalation study of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. Proc Am Soc Clin Oncol 2002;21:110a.
11. Anderson H, Price P, Blomley M, Leach MO, Workman P. Measuring changes in human tumour vasculature in response to therapy using functional imaging techniques. Br J Cancer 2001;85:1085-93.
12. Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 2002;16:407-22.
13. Maxwell RJ, Wilson J, Prise VE, et al. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 2002;15:89-98.
14. Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE, Brindle KM. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 1998;77:1761-7.
15. Beauregard DA, Hill SA, Chaplin DJ, Brindle KM. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res 2001;61:6811-5.
16. Leach MO, Brindle KM, Evelhoch JL, et al. Assessment of anti-angiogenic and anti-vascular therapeutics using magnetic resonance imaging: recommendations for appropriate methodology for clinical trials. Proc Am Assoc Cancer Res 2003;44:115.
17. Brookes JA, Redpath TW, Gilbert FJ, Murray AD, Staff RT. Accuracy of T1 measurement in dynamic contrast-enhanced breast MRI using two- and three-dimensional variable flip angle fast low-angle shot. J Magn Reson Imaging 1999;9:163-71.
18. Donahue KM, Weisskoff RM, Burstein D. Water diffusion and exchange as they influence contrast enhancement. J Magn Reson Imaging 1997;7:102-10.
19. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 1999;19:189-95.
20. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997;57:1829-34.
21. Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831-42.
22. Beauregard DA, Pedley RB, Hill SA, Brindle KM. Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR Biomed 2002;15:99-105.
23. Dowlati A, Robertson K, Cooney M, et al. A Phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-16.
24. Galbraith SM, Rustin GJ, Lodge MA, et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol 2002;20:3826-40.
25. Robinson SP, McIntyre DJ, Checkley D, et al. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 2003;88:1592-7.
26. Blakey DC, Ashton SE, Westwood FR, Walker M, Ryan AJ. ZD6126: a novel small molecule vascular targeting agent. Int J Radiat Oncol Biol Phys 2002;54:1497-502.
27. Galbraith SM, Lodge MA, Taylor NJ, et al. Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed 2002;15:132-42.
28. Knopp MV, Giesel FL, Marcos H, von Tengg-Kobligk H, Choyke P. Dynamic contrast-enhanced magnetic resonance imaging in oncology. Top Magn Reson Imaging 2001;12:301-8.
29. Gossmann A, Helbich TH, Kuriyama N, et al. Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme. J Magn Reson Imaging 2002;15:233-40.
30. Drevs J, Muller-Driver R, Wittig C, et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 2002;62:4015-22.
31. Rijpkema M, Kaanders JH, Joosten FB, van der Kogel AJ, Heerschap A. Method for quantitative mapping of dynamic MRI contrast agent uptake in human tumors. J Magn Reson Imaging 2001;14:457-63.
32. Evelhoch JL, He Z, Polin L, Corbett TH, Blakey DC, Waterton JC. Dynamic contrast-enhanced MRI evaluation of the effects of ZD6126 on tumor vasculature. Proc Int Soc Magn Reson Med 2001;9:481.